haematology
Blood cancers

New treatment option for people with CLL/SLL and FL

The oral phosphatidylinosital 3-kinase inhibitor idelalisib (Zydelig) is now available on the PBS for eligible patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia and relapsed or refractory follicular lymphoma. Without the subsidy the drug would cost $60,500 a year for follicular lymphoma patients and $115,800 a year for chronic lymphocytic leukaemia or ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic